• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·688085.SS
Share

Shanghai Sanyou Medical Co., Ltd Stocks

CN¥ 13.2Last Updated 15.07.2026

Issuer Rating

4/7
Performance

Modest

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 670.72M

CN¥ 13.2
Key Takeaways

Risk factor

Fair trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Headquartered in Shanghai, China, Shanghai Sanyou Medical Co., Ltd. focuses on the entire lifecycle of orthopedic implants, from their initial research and development through manufacturing and ultimately sales within the Chinese market. The company distributes its medical devices under the Tytus and Sanyou brand names, primarily specializing in spinal and trauma-related implants. Its spinal product line features a broad selection, including anterior cervical plates, anterior and posterior thoracolumbar systems, posterior cervical solutions, and z-minimally invasive products. For trauma injuries, Sanyou Medical offers implant systems designed for various anatomical regions, such as the shoulder and elbow, hip and pelvis, knee, and palm and wrist.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. Specifically, the stock is 'expensive' on P/E, overvalued on EV/EBI

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

15.07.2026 19:06

Oppenheimer withdrew its recommendation to buy IBM stock following its historic plunge

15.07.2026 18:44

Kaspi.kz has completed the acquisition of Turkey's Rabobank

15.07.2026 18:25

Shares of a mid-cap company that develops chip-testing solutions have skyrocketed. Why?

15.07.2026 18:04

Wholesale prices in the U.S. fell in June—a development the market did not expect

15.07.2026 17:30

Assets under management at BlackRock exceeded $15 trillion for the first time

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026